Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Antiviral Effect and Safety of Once Daily BI 201335 NA in Hepatitis C Virus Genotype 1 Infected Treatment-naive Patients for 12 or 24 Weeks as Combination Therapy With Pegylated Interferon-alpha 2a and Ribavirin (Randomised, Open Label, Phase II)

NCT00984620 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00984620
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00984620 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Antiviral Effect and Safety of Once Daily BI 201335 NA in Hepatitis C Virus Genotype 1 Infected Treatment-naive Patients for 12 or 24 Weeks as Combination Therapy With Pegylated Interferon-alpha 2a and Ribavirin (Randomised, Open Label, Phase II)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2009
Completion date
Not reported
Enrollment
160 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c